Announcements Trials
Browse Landscape

Phase

Phase 1/2 3Phase 2 1Phase 1 1

Status

Recruiting 2Not yet recruiting 1Completed 1Active not recruiting 1

Sponsor Class

OTHER 3INDUSTRY 2

Study Type

Interventional 5

Sponsor

Cancer Type

Gynecologic 2Dermatologic 1CNS 1

Conditions

Melanoma 52Carcinoma, Non-Small-Cell Lung 51Carcinoma, Renal Cell 34Lung Neoplasms 23Neoplasm Metastasis 21Carcinoma, Hepatocellular 21Stomach Neoplasms 17Squamous Cell Carcinoma of Head and Neck 17Colorectal Neoplasms 15Neoplasms 14Carcinoma, Transitional Cell 14Adenocarcinoma Of Esophagus 13Hodgkin Disease 10Brain Neoplasms 10Urinary Bladder Neoplasms 9Prostatic Neoplasms 9Ovarian Neoplasms 8Multiple Myeloma 8Esophageal Neoplasms 8Triple Negative Breast Neoplasms 7Skin Neoplasms 7Sarcoma 7Rectal Neoplasms 7Colonic Neoplasms 7Clear-cell metastatic renal cell carcinoma 7Breast Neoplasms 7Pancreatic Neoplasms 6Carcinoma, Merkel Cell 6Carcinoma, Basal Cell 6Uveal Melanoma 5

Interventions

Cyclophosphamide 25fludarabine 19Dexamethasone 17pembrolizumab 13Rituximab 12venetoclax 9Lenalidomide 9Gemcitabine 9Etoposide 9pomalidomide 8Vincristine 7glofitamab 6fludarabine phosphate 6carfilzomib 6Temozolomide 6obinutuzumab 5daratumumab 5Prednisone 5Nivolumab 5Doxorubicin 5Cisplatin 5Calcium Dobesilate 5Bortezomib 5zanubrutinib 4selinexor 4Immunotherapy, Adoptive 4Cytarabine 4Carboplatin 4Azacitidine 4ruxolitinib 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Recurrence × Nivolumab × 90 days × Clear all
NCT03686124 2026-05-13

ACTengine

Immatics US, Inc.

Phase 1/2 Recruiting
375 enrolled
DermatologicGynecologic

Uveal Melanoma, Melanoma, Neoplasms, Ovarian Neoplasms, Recurrence

NCT02379520 2026-04-15

HESTIA

Baylor College of Medicine

Phase 1 Completed
32 enrolled

Neoplasms, Recurrence

NCT05533697 2026-04-03

Study of mRNA-4359 Administered Alone and in Combination With Immune Checkpoint Blockade in Participants With Advanced Solid Tumors

ModernaTX, Inc.

Phase 1/2 Recruiting
361 enrolled

Neoplasm Metastasis, Neoplasms, Recurrence

NCT03355976 2026-04-02

BrUOG 354 Nivolumab +/- Ipilimumab for Ovarian and Extra-renal Clear Cell Carcinomas

Brown University

Phase 2 Active not recruiting
46 enrolled
Gynecologic

Fallopian Tube Neoplasms, Ovarian Neoplasms, Recurrence, Adenocarcinoma, Clear Cell

NCT06639607 2026-03-10

PRiME II

Washington University School of Medicine

Phase 1/2 Not yet recruiting
68 enrolled
CNS

Diffuse Intrinsic Pontine Glioma, Ependymoma, Medulloblastoma, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡